Diamyd Medical is currently conducting a Phase III clinical trial in recent onset type 1 diabetes patients in the USA - the DiaPrevent research study.
The purpose of the research and study is to investigate whether the investigational Diamyd
® diabetes vaccine can preserve residual insulin production in children and young adults with recent onset type 1 diabetes.
For more information about this US study, please visit the
DiaPrevent research study website.